Services

Start Your Project Now!

Please note: Our products and services are not intended to be used directly in diagnostic or therapeutic procedures.

Here's how you can reach us...

Tel:
Email:

Nasal Nucleic Acid Formulation Development

Inquiry

CD Formulation has launched an innovative nasal nucleic acid formulation development service aimed at advancing new methodologies in nasal delivery systems. Our service combines the company's expertise in drug development and delivery systems to offer comprehensive support from concept validation to product specifications, ensuring the stability and effectiveness of nucleic acid molecules.

Why Engage in Nasal Nucleic Acid Formulation Development?

The nasal drug delivery system is a non-invasive administration route that bypasses the first-pass metabolism, offers rapid onset, and provides brain-targeting capabilities, making it a viable alternative to injectable routes and a potential pathway for central nervous system applications. However, the nasal physiological environment is complex, and as a ‘drug-device combination,' the efficiency of nasal drug delivery is influenced by factors such as the drug, formulation, device, and nasal physiology. Strategies like modifying the physicochemical properties of drugs, adding enzyme inhibitors or absorption enhancers to formulations, and designing novel drug carriers can improve drug solubility, stability, membrane permeability, and nasal retention time, thereby enhancing nasal drug delivery efficiency.

Fig.1 Features of nasal nucleic acid formulations. Fig.1 The characteristics of nasal nucleic acid formulation. (CD Formulation)

Explore Our Nasal Nucleic Acid Formulation Development Services

Items	Descriptions
Development of Nasal Drops	As a simple and economical nasal delivery system, the development of nasal drops needs to focus on addressing dosing control and contamination during use. Typically delivered via droppers or squeeze bottles, development should prioritize inhibiting microbial growth, maintaining mucociliary function, and minimizing nonspecific drug loss.
Development of Nasal Sprays	Nasal spray development primarily aims to enhance dosage accuracy and consistency. Spray formulation involves optimizing chamber, piston, and actuator designs, along with repeated testing and refinement in formulation characteristics such as thixotropy, surface tension, and viscosity to ensure droplet size and dosage precision.
Development of Nasal Gels	Nasal gel development requires in-depth study of how polymer types and concentrations affect gel rheological properties. The semi-solid behavior of gels is determined by their elastic and viscous moduli, so development must finely tune these parameters to achieve appropriate drug release rates and adhesion, thereby enhancing formulation stability and extending retention time.
Development of Nasal Powders	Powder inhaler development focuses on the interaction between the drug and excipients, prepared through spray drying or freeze-drying techniques. Consideration of powder retention time and hygroscopic capacity within the nasal cavity during development is crucial to ensure sufficient retention and release characteristics after forming a gel, enhancing absorption rates.
Development of Nasal Aerosols	Aerosol development targets improved spray efficiency and drug stability using propellant-generated pressures to expel the drug. Challenges include propellant selection and specialized valve system design, ensuring stable delivery of the drug in its physical form to the nasal cavity.
Development of Nasal Microspheres	Microspheres enhance drug absorption by increasing adhesion and extending retention time in nasal formulation development. Focus is on selecting materials for microspheres and their gelation characteristics post-hydration to optimize release profiles and validate their persistence within the nasal cavity through systematic experiments.
Development of Nasal Suspensions and Emulsions	The development of nasal suspensions and emulsions emphasizes improving drug solubility by formulating with lipophilic absorption promoters to enhance nasal absorption efficiency. Consideration of microcrystal structure and emulsifier selection and their effects on stability and absorption enhancement are crucial to ensure optimized release within the nasal cavity.
Development of Nasal Micelles and Liposome Formulations	Nasal applications of micelles and liposomes development mainly explore their potential to enhance drug absorption, optimizing micelle solubilization with surface-active agents such as bile salts. Experimental determination of the best excipient combinations during development enhances the permeability of hydrophilic macromolecule drugs.

Our Solutions for Improving Nasal Drug Delivery Efficiency

Modification of Physicochemical Properties

By adjusting the chemical structure of drugs, one can improve solubility, stability, and bio-permeability. For instance, transforming lipophilic drugs into more water-soluble prodrugs to prepare suitable concentrations for nasal solutions. Likewise, polar drugs can be modified into more lipophilic prodrugs to increase membrane permeability, which also enhances enzyme stability.

Use of Enzyme Inhibitors

The presence of metabolic enzymes in the nasal cavity can affect drug activity, so protease and peptidase inhibitors are often added to prevent drug degradation. Additionally, certain absorption enhancers can also inhibit enzyme activity, thereby improving drug stability and absorption efficiency.

Application of Absorption Enhancers

Changing the molecular alignment of cell membrane phospholipids, increasing membrane fluidity, and opening tight junctions among epithelial cells enhances drug permeability. Common enhancers include surfactants and polymer promotors, with the latter being preferred for causing less mucosal damage.

Introduction of Drug Carriers

Employing carriers like liposomes, microspheres, and nanoparticles improves the efficiency of nasal drug delivery. Liposomes can effectively encapsulate drugs, enhancing enzyme stability and bioadhesion. Microspheres significantly prolong retention time, achieving sustained release. Nanoparticles offer strong adhesion, extending retention time, and exhibit good brain targeting and sustained release properties.

Our Workflow for Nasal Nucleic Acid Formulation Development

Fig.2 Diagram illustrating the development process for nasal nucleic acid formulations. Fig.2 Flow chart of nasal nucleic acid formulation development. (CD Formulation)

Needs Assessment

Begin with a thorough needs analysis to determine the characteristics of the target nucleic acid molecules, required delivery efficiencies, and other key parameters to develop suitable nasal formulations.

Formulation Design

Based on initial assessment results, scientifically formulate compositions. Choose appropriate excipients and absorption promoters, ensuring the nucleic acid molecules' stability and effective transmission within the nasal cavity.

Process Optimization

Select and optimize manufacturing processes to ensure uniformity and quality control. Process parameters such as stirring speeds, temperature, and pH adjustments are crucial steps for ensuring the final product quality.

Stability Testing

Conduct comprehensive stability trials to assess formulation integrity and functionality under various environmental conditions. Monitor nucleic acid degradation and physical stability of the entire formulation system.

Our Technology Platforms

Items	Descriptions
Nucleic Acid Formulation Preparation Technology	This platform focuses on optimizing the stability and bioavailability of nucleic acid components within formulations through careful selection of carrier materials and auxiliary materials. Preparation techniques range from solutions to solid powders, accommodating various storage and transport conditions.
Nucleic Acid Drug Delivery Platforms	The platform is dedicated to developing advanced delivery systems to optimize nucleic acid transport and targeting within the body. This includes using carriers like liposomes and nanoparticles to increase cellular uptake efficiency and reduce degradation rates. Research on overcoming biological barriers ensures efficient delivery to target sites.
Analytical Technology Platforms	Providing a comprehensive set of tools and techniques, the analytical technology platform evaluates the quality and performance of nasal nucleic acid formulations. Including advanced component analysis, structural identification, and stability testing methods, ensuring products meet standards. These technologies help identify and resolve potential formulation issues, ensuring consistency and reliability in production and application.

Our Advantages of Nasal Nucleic Acid Formulation Development

Advanced technical methods allow for precise formulation of nucleic acid components, ensuring efficiency and stability in complex environments.
We offer flexible transmission platforms for personalized adjustments to maximize effects and optimize development.
We utilize a comprehensive analytical technology platform to ensure high production standard compliance regarding composition, purity, and stability, enhancing development efficiency and reducing risks.
Fostering close collaborations, the integration of versatile resources and expertise forms a complete support ecosystem to increase project success rates.

Publication Data

Technology: Development of RNA therapeutics utilizing inhalation delivery technology

Journal: Journal of Controlled Release

IF: 10.5

Published: 2024

Results:

Delivering RNA through inhalation is an appealing non-invasive method, offering a promising alternative to traditional injections. Nebulized inhalation stands out due to its capacity to administer substantial RNA doses during natural breathing cycles. This overview examines the challenges presented by lung physiology in nebulized RNA delivery and explores strategies to overcome these obstacles. Additionally, it highlights the role of effective delivery systems, analyzing various lipid-based, polymeric, and hybrid vehicles utilized in RNA nebulization research.

Fig.3 Transitioning RNA formulations from aerosol to cellular uptake in lung delivery. Fig.3 Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol. (Neary M T, et al., 2024)

CD Formulation stands at the forefront of innovating nasal nucleic acid formulations, providing expertise and advanced technologies to address complex delivery challenges. Our customized approaches are crafted to optimize formulation performance and meet your specific project goals. Connect with us to discover how our solutions can elevate your nasal delivery initiatives and foster successful collaborations.

References

Neary M T, Mulder L M, Kowalski P S, et al. Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol. J Control Release. 2024, 366: 812-833.

How It Works

STEP 1

Submit a service request describing your specific research or development need.

STEP 2

We'll email you to provide your quote and confirm order details if applicable.

STEP 3

Execute the project with real-time communication, and deliver the final report promptly.

Related Services